Marshall Wace, LLP Annexon, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Annexon, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 38,845 shares of ANNX stock, worth $102,550. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,845
Previous 292,374
86.71%
Holding current value
$102,550
Previous $1.73 Million
88.5%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ANNX
# of Institutions
156Shares Held
98.2MCall Options Held
146KPut Options Held
174K-
Satter Management Co., L.P.7.41MShares$19.6 Million71.99% of portfolio
-
Bvf Inc San Francisco, CA7MShares$18.5 Million1.34% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$17.4 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.3MShares$16.6 Million2.53% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.63MShares$14.9 Million0.07% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $126M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...